Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Taking cancer on through research and clinical collaboration
Transforming bright scientific ideas into new treatments for patients increasingly requires a strong, international network of partners. Boehringer Ingelheim is dedicated to collaborating with researchers and the wider oncology community to deliver leading science and breakthrough therapies.
Read more about our ongoing collaborations below.
Our research collaborations
We are developing a growing collaborative network with academic centres and biotechnology companies, reflecting our focus on leading science. Our research collaborators include:
University of Dundee
We have joined forces with the University of Dundee to develop PROteolysis TArgeting Chimeric molecules (PROTACs) as new therapeutic modalities. Dr Alessio Ciulli, based at the School of Life Sciences at Dundee, is one of the pioneers in the field of PROTACs, which target disease-causing proteins for degradation by the ubiquitin-proteasome system.1
This collaboration to discover next-generation therapeutic antibodies in oncology focuses on utilising proprietary human sequence antibody libraries and a unique technology platform to identify antibodies against intracellular proteins.2
MD Anderson Cancer Center
We are collaborating with the MD Anderson Cancer Center to develop innovative medicines for pancreatic cancer.3
We have entered into two multi-year research programmes with the cancer drug research laboratory of Professor Stephen Fesik at Vanderbilt University. These programmes focus on therapies targeting Ras, which is one of the most frequently mutated oncogenes in cancer.4
This collaboration with Yale University aims to develop new immune-modulatory agents for oncology, autoimmune diseases and respiratory diseases.5
National Cancer Center, Japan
We are working together with the National Cancer Center, Japan, to carry out early drug discovery and translational research focusing on specific biomarkers and tumour types that are prevalent in Asia.6
Our clinical collaborations
We are involved in a number of collaborations in clinical research, including:
Sarah Cannon Research Institute
We have formed a strategic collaboration with the Sarah Cannon Research Institute to study BI 754091,* an anti-programmed death-1 monoclonal antibody, and BI 754111,* an anti-lymphocyte-activation gene-3 monoclonal antibody, for the combination treatment of various cancers including non-small cell lung cancer (NSCLC).7
We have partnered with CureVac to develop the mRNA-based immunotherapeutic cancer vaccine BI 1361849* (CV9202). BI 1361849 is currently being investigated as a treatment for NSCLC in combination with other checkpoint inhibitors.8
We are collaborating with Eli Lilly to investigate xentuzumab* in combination with the cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitor abemaciclib in patients with metastatic breast cancer.9
We are collaborating with MSD to investigate afatinib§ in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung (the LUX-Lung IO trial).10
We have joined forces with Philogen to investigate F16-IL-2 teleukin,* an immunostimulatory ‘empowered antibody’, in combination with BI 836858,* an anti-CD33 monoclonal antibody, in patients with acute myeloid leukaemia (AML) who have relapsed after allogeneic haematopoietic stem cell transplantation.11‒13
The Leukemia & Lymphoma Society
We are contributing to a first-of-its-kind collaborative trial programme to advance treatments for patients with AML, organised by the Leukemia & Lymphoma Society. The Beat AML Master Trial is investigating several medicines from different biopharmaceutical companies. Within the trial, newly diagnosed patients are assigned to a treatment arm based on genomic analysis. The investigational anti-CD33 monoclonal antibody, BI 836858,* will be provided as one of the treatment options.14
In partnership with OSE Immunotherapeutics, we are developing a pioneering checkpoint inhibitor for the treatment of advanced, solid tumours. OSE-172* is an anti-signal-regulatory protein-alpha monoclonal antibody targeting myeloid lineage cells.15
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-university-dundee-collaborate (Accessed: November 2018).
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/eureka-therapeutics-inc-and-boehringer-ingelheim-announce-collaboration-identify-next (Accessed: November 2018).
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-md-anderson-join-forces (Accessed: November 2018).
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-vanderbilt-join-forces-develop-new-ras-inhibitors-cancer (Accessed: November 2018).
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-yale-university-collaborate-investigate-novel-immunotherapy (Accessed: November 2018).
National Cancer Center, Japan. Press release. https://www.ncc.go.jp/jp/information
/pr_release/2017/0711/press_release_20170711.pdf (Accessed November 2018)
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/sarah-cannon-collaboration (Accessed: November 2018).
Clinical trials.gov. NCT03164772. https://clinicaltrials.gov/ct2/show/ NCT03164772 (Accessed: November 2018).
Clinical trials.gov. NCT03099174. https://clinicaltrials.gov/ct2/show/ NCT03099174 (Accessed: November 2018).
Clinical trials.gov. NCT03157089. https://clinicaltrials.gov/ct2/show/NCT03157089 (Accessed: November 2018).
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-philogen-partner-aml (Accessed: November 2018).
Philogen website. http://www.philogen.com/en/products/teleukin_10.html (Accessed: November 2018).
Clinical trials.gov. NCT03207191. https://clinicaltrials.gov/ct2/show/NCT03207191 (Accessed: December 2018).
Clinical trials.gov. NCT03013998. https://clinicaltrials.gov/ct2/show/NCT03013998 (Accessed: November 2018).
Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/New-Partnership-to-develop-novel-checkpoint-inhibitor (Accessed: November 2018).
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established; §Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information; ¶ Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: January 2019
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue